Unite. Act. Eliminate.

Calls for unity, action and concerted efforts to address inequalities that drive NTDs

Since World Health Organization (WHO) NTD roadmap (2021–2030) was released, significant milestones have been achieved. By the end of 2023, 50 countries had eliminated at least one NTD. These successes can be attributed to country ownership, partnerships and concerted fundraising and commitments, such as the Kigali Declaration.

Progress in ending NTDs depends on better diagnostic tools

Our work includes compiling a transparent diagnostic pipeline tailored to needs identified in the WHO roadmap and advocacy to address critical product and funding gaps, as well as development and support for local production of rapid diagnostic tests.

Our portfolio spans those NTDs with the greatest diagnostic gaps: Buruli ulcer, Chagas disease, sleeping sickness (human African trypanosomiasis or HAT), visceral leishmaniasis (kala-azar), lymphatic filariasis, onchocerciasis and schistosomiasis. Our technical experts contribute to the WHO Diagnostics Technical Advisory Group (DTAG) in defining gaps and coordinating the development of target product profiles for priority use cases.

Together, we can make a lasting impact.  

Political commitment and the momentum towards sustainable progress are critical to accelerating progress and expanding access to diagnostics and treatment for NTDs. We must unite, act, and eliminate NTDs.

Trypa-NO! partnership

In 2023 we announced a 3-year extension to our ongoing work with the Trypa-NO! partnership – a project led by FIND, the French National Research Institute for Sustainable Development (IRD), and the Liverpool School of Tropical Medicine (LSTM) – that has so far supported Chad, Côte d’Ivoire, Guinea and Uganda to progress towards elimination of sleeping sickness. 

Read our press release